Salvus Wealth Management LLC Buys Shares of 5,485 GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Salvus Wealth Management LLC acquired a new position in GE HealthCare Technologies Inc. (NASDAQ:GEHC - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 5,485 shares of the company's stock, valued at approximately $429,000.

A number of other large investors have also modified their holdings of the company. E Fund Management Co. Ltd. lifted its position in shares of GE HealthCare Technologies by 6.8% during the 2nd quarter. E Fund Management Co. Ltd. now owns 6,782 shares of the company's stock valued at $528,000 after buying an additional 430 shares in the last quarter. Mercer Global Advisors Inc. ADV raised its position in GE HealthCare Technologies by 15.7% during the second quarter. Mercer Global Advisors Inc. ADV now owns 24,326 shares of the company's stock worth $1,931,000 after acquiring an additional 3,303 shares during the period. Meiji Yasuda Asset Management Co Ltd. lifted its holdings in GE HealthCare Technologies by 16.8% during the second quarter. Meiji Yasuda Asset Management Co Ltd. now owns 6,771 shares of the company's stock valued at $528,000 after purchasing an additional 976 shares in the last quarter. Amalgamated Bank grew its position in shares of GE HealthCare Technologies by 2.6% in the second quarter. Amalgamated Bank now owns 85,418 shares of the company's stock valued at $6,656,000 after purchasing an additional 2,188 shares during the period. Finally, Vanguard Personalized Indexing Management LLC increased its stake in shares of GE HealthCare Technologies by 10.9% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 30,684 shares of the company's stock worth $2,391,000 after purchasing an additional 3,020 shares in the last quarter. Institutional investors and hedge funds own 82.06% of the company's stock.

Insider Activity at GE HealthCare Technologies

In related news, CEO Roland Rott sold 3,577 shares of the stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $86.48, for a total transaction of $309,338.96. Following the completion of the transaction, the chief executive officer now owns 24,298 shares of the company's stock, valued at approximately $2,101,291.04. This trade represents a 12.83 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.27% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on GEHC. Jefferies Financial Group raised shares of GE HealthCare Technologies from a "hold" rating to a "buy" rating and raised their price target for the company from $95.00 to $103.00 in a research note on Wednesday, January 8th. UBS Group downgraded GE HealthCare Technologies from a "neutral" rating to a "sell" rating and decreased their target price for the company from $84.00 to $74.00 in a research report on Thursday, September 26th. Stifel Nicolaus boosted their price target on GE HealthCare Technologies from $100.00 to $102.00 and gave the stock a "buy" rating in a research report on Monday, September 30th. Wells Fargo & Company raised their price objective on GE HealthCare Technologies from $95.00 to $96.00 and gave the company an "overweight" rating in a report on Thursday, October 31st. Finally, Evercore ISI upped their target price on shares of GE HealthCare Technologies from $98.00 to $102.00 and gave the stock an "outperform" rating in a report on Tuesday, October 1st. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $96.00.

GE HealthCare Technologies Trading Down 0.3 %

GEHC stock traded down $0.26 during trading on Friday, reaching $84.74. 2,855,039 shares of the stock were exchanged, compared to its average volume of 3,233,667. The business has a 50 day moving average price of $82.00 and a 200-day moving average price of $84.27. GE HealthCare Technologies Inc. has a 1 year low of $71.31 and a 1 year high of $94.55. The company has a current ratio of 1.23, a quick ratio of 0.98 and a debt-to-equity ratio of 1.12. The firm has a market capitalization of $38.72 billion, a price-to-earnings ratio of 23.28, a P/E/G ratio of 2.80 and a beta of 1.11.

GE HealthCare Technologies (NASDAQ:GEHC - Get Free Report) last released its quarterly earnings data on Wednesday, October 30th. The company reported $1.14 EPS for the quarter, beating analysts' consensus estimates of $1.06 by $0.08. The firm had revenue of $4.86 billion for the quarter, compared to analysts' expectations of $4.87 billion. GE HealthCare Technologies had a return on equity of 25.19% and a net margin of 8.56%. The firm's quarterly revenue was up .9% on a year-over-year basis. During the same period in the prior year, the firm posted $0.99 earnings per share. On average, research analysts predict that GE HealthCare Technologies Inc. will post 4.3 earnings per share for the current year.

GE HealthCare Technologies Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, February 14th. Investors of record on Tuesday, January 14th will be given a dividend of $0.035 per share. This represents a $0.14 dividend on an annualized basis and a dividend yield of 0.17%. This is an increase from GE HealthCare Technologies's previous quarterly dividend of $0.03. The ex-dividend date is Tuesday, January 14th. GE HealthCare Technologies's dividend payout ratio (DPR) is presently 3.30%.

About GE HealthCare Technologies

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.